t-Branch 即用型多分支内移植物择期与紧急治疗胸腹主动脉瘤短期及中期结局的系统评价与荟萃分析
该系统评价与荟萃分析检索 PubMed、Embase 和 Web of Science(2012年6月至2023年3月),纳入15项研究共1238例患者,评估 t-Branch 即用型多分支内移植物治疗胸腹主动脉瘤的安全性和有效性。汇总技术成功率为97.0%,早期死亡率为7.3%,早期脊髓缺血为13.4%,中期靶血管闭塞为4%,中期再干预为11.2%。作者认为该装置早期和中期随访安全有效,但研究间异质性高,需要前瞻性随机研究及未来更大样本的长期随访研究。
要点
- 汇总技术成功率为97.0%(95%CI=95.5-98.6,I²=53.01%,1185/1238例,15项研究)。
- 早期死亡率为7.3%(95%CI=4.4-10.1,I²=74.48%,124/1238例,15项研究)。
- 中期再干预率为11.2%(95%CI=8.1-14.3,I²=31.06%,85/650例,10项研究,5-21.2个月)。
核心结论
- 使用即用型 t-Branch 多分支内移植物进行择期或紧急血管内胸腹主动脉瘤修复与高技术成功率相关,并在早期和中期随访中证明安全有效。
- 然而纳入研究间异质性高,需要前瞻性随机研究以及未来更大样本的长期随访研究。
研究设计与样本
- 系统评价与荟萃分析,检索 PubMed、Embase 和 Web of Science,检索时间为2012年6月至2023年3月。
- 纳入15项研究共1238例患者,使用随机效应模型汇总比例,并进行亚组荟萃分析和荟萃回归探索研究间变异。
- 总体研究质量评估为中等至良好。
主要发现
- 汇总技术成功率为97.0%(95%CI=95.5-98.6,I²=53.01%,1185/1238例,15项研究)。
- 早期死亡率为7.3%(95%CI=4.4-10.1,I²=74.48%,124/1238例,15项研究)。
- 早期脊髓缺血为13.4%(95%CI=9.6-17.2,I²=67.24%,160/1238例,15项研究),早期I型或III型内漏为6.0%(95%CI=3.4-8.5,I²=53.71%,68/1032例,9项研究)。
- 中期靶血管闭塞为4%(95%CI=1.4-6.5,I²=65.18%,28/528例,10项研究,5-21.2个月),中期I型或III型内漏为4.7%(95%CI=2-7.5,I²=49.74%,38/512例,10项研究,5-21.2个月)。
- 中期再干预为11.2%(95%CI=8.1-14.3,I²=31.06%,85/650例,10项研究,5-21.2个月),汇总死亡率为13.9%(95%CI=7.2-20.7,I²=76.32%,84/550例,11项研究,5-21.2个月)。
临床怎么用
- 作者认为,即用型 t-Branch 多分支内移植物用于择期或紧急血管内胸腹主动脉瘤修复与高技术成功率相关,并在早期和中期随访中证明安全有效。
- 作者指出研究间异质性高,需要前瞻性随机研究以及未来更大样本的长期随访研究。
- 作者认为本荟萃分析结果对血管内外科医生在胸腹主动脉瘤患者治疗决策中有帮助。
局限性
- 纳入研究间异质性高(如早期死亡率 I²=74.48%、中期死亡率 I²=76.32%)。
- 需要前瞻性随机研究以及未来更大样本的长期随访研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a meta-analysis to assess the safety and efficacy of t-Branch off-the-shelf multibranched endograft for the treatment of thoracoabdominal aortic aneurysm (TAAA). DATA SOURCES: PubMed, Embase, and Web of Science. REVIEW METHODS: Online databases were searched from June 2012 to March 2023. The data were pooled together using a random-effects model of proportions. The outcomes overall included technical success, spinal cord ischemia, target vessel occlusion, type I or III endoleak, reintervention, early mortality (30-day), and mid-term outcomes. Subgroup meta-analyses and meta-regression were performed to explore variation among studies. RESULTS: A total of 15 studies containing 1238 patients were included in the meta-analysis. The overall study quality assessment was found to be moderate to good. The pooled technical success was 97.0% (95% confidence interval [CI]=95.5-98.6, I2=53.01%, 1185/1238 cases, 15 studies). Overall, early mortality was 7.3% (95% CI=4.4-10.1, I2=74.48%, 124/1238 cases, 15 studies). Early spinal cord ischemia was 13.4% (95% CI=9.6-17.2, I2=67.24%, 160/1238 cases, 15 studies), and early type I or III endoleak was 6.0% (95% CI=3.4-8.5, I2=53.71%, 68/1032 cases, 9 studies). Mid-term outcomes showed target vessel occlusion was 4% (95% CI=1.4-6.5, I2=65.18%, 28/528 cases, 10 studies, 5-21.2 months), type I or III endoleak was 4.7% (95% CI=2-7.5, I2=49.74%, 38/512 cases, 10 studies, 5-21.2 months), reintervention was 11.2% (95% CI=8.1-14.3, I2=31.06%, 85/650 cases, 10 studies, 5-21.2 months), and pooled mortality was 13.9% (95% CI=7.2-20.7, I2=76.32%, 84/550 cases, 11 studies, 5-21.2 months). Meta-regression found a significant linear association between higher technical success and earlier publication year (p=0.014) and studies with anatomic inclusion criteria (p=0.037). Urgent patients (p=0.021) and later publication year (p=0.048) were significantly associated with higher early mortality. CONCLUSION: The use of the off-the-shelf t-Branch multibranched endograft for elective or urgent endovascular TAAA repair is associated with high technical success rates and proved to be safe and effective at early and mid-term follow-up. However, the heterogeneity between the included studies is high, and prospective, randomized studies along with future larger studies with long-term follow-up are needed.Clinical ImpactThe Zenith t-Branch (Cook Medical, Bloomington, Ind) was approved as a commercially available device in Europe in June 2012. Although a decade has past, the outcomes of t-Branch have rarely been synthesized at the global level. This meta-analysis included 15 studies containing 1238 patients. The meta-analyses included technical success, major adverse events, reintervention, early mortality, and mid-term outcomes. The outcome was very meaningful and representative for the use of t-Branch. It is helpful for endovascular surgeons to make decisions on the treatment of TAAA patients.
引用
- Chen Y, Liu Z, Wang S, et al. Systematic Review and Meta-analysis of Short-term and Mid-term Outcomes After Use of t-Branch Off-the-shelf Multibranched Endograft for Elective and Urgent Treatment of Thoracoabdominal Aortic Aneurysms. J Endovasc Ther. 2023. PMID: 38158706. doi:10.1177/15266028231220322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。